Teva Pharmaceuticals Industries' (TEVA) US affiliate, Teva Pharmaceuticals, said Monday that its biosimilar Epysqli, developed in collaboration with Samsung Bioepis, is now available in the US to treat rare conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
Epysqli was approved by the US Food and Drug Administration last year, and it will be priced 30% below Soliris, the brand-name equivalent, Teva said.
The FDA has provisionally determined that Epysqli will be interchangeable with Soliris once the first interchangeable biosimilar's exclusivity period expires, the company said.
Shares of the company were up more than 4% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。